EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

H 2 inhalation therapy in patients with moderate COVID-19 (H 2 COVID): a prospective ascending-dose phase I clinical trial

C Salomez-Ihl iD, J Giai, M Barbado, A Paris, S Touati, J P Alcaraz, S Tanguy, C Leroy, A Lehmann, B Degano, M Gavard, P Bedouch und 6 weitere

Antimicrobial Agents and Chemotherapy · 07.08.2024 · 68 (8)

DOI: 10.1128/aac.00573-24 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.08.2024. Verfasst von C Salomez-Ihl und 17 weiteren Autor:innen. Beteiligte Einrichtung: Université Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, CHU Grenoble Alpes, TIMC, UMR5525, Grenoble, France. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered a serious global health crisis, resulting in millions of reported deaths since its initial identification in China in November 2019. The global disparities in immunization access emphasize the urgent need for ongoing research into therapeutic interventions. This study focuses on the potential use of molecular dihydrogen (H2) inhalation as an adjunctive treatment for COVID-19. H2 therapy shows promise in inhibiting intracellular signaling pathways associated with inflammation, particularly when administered early in conjunction with nasal oxygen therapy. This phase I study, characterized by an open-label, prospective, monocentric, and single ascending-dose design, seeks to assess the safety and tolerability of the procedure in individuals with confirmed SARS-CoV-2 infection. Employing a 3 + 3 design, the study includes three exposure durations (target durations): 1 day (D1), 3 days (D2), and 6 days (D3). We concluded that the maximum tolerated duration is at least 3 days. Every patient showed clinical improvement and excellent tolerance to H2 therapy. To the best of our knowledge, this phase I clinical trial is the first to establish the safety of inhaling a mixture of H2 (3.6%) and N2 (96.4%) in hospitalized COVID-19 patients. The original device and method employed ensure the absence of explosion risk. The encouraging outcomes observed in the 12 patients included in the study justify further exploration through larger, controlled clinical trials. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT04633980 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2HumansMaleMiddle AgedAdministration, InhalationProspective StudiesFemaleAdultPandemicsAgedCOVID-19 Drug Treatment

Stichwörter der Autor:innen

COVID-19administration, inhalationmolecular hydrogen

Autor:innen und Institutionen

  • Université Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, CHU Grenoble Alpes, TIMC, UMR5525, Grenoble, France.
  • Department of Pharmacy, Université Grenoble Alpes, CHU Grenoble Alpes, Grenoble, France.
  • Univ. Grenoble Alpes, Inserm, CHU Grenoble Alpes, Centre for Clinical Investigation, Grenoble, France.
  • Department of Infectious and Tropical Diseases, CHU Grenoble Alpes, Grenoble, France.
  • Department of Pneumology, CHU Grenoble Alpes, Grenoble, France.
  • CHU Grenoble Alpes, Delegation for Clinical Research and Innovation, Grenoble, France.

ORCID-Profile: C Salomez-Ihl, F Boucher, P Cinquin, J P Brion

Zitieren

APA

Salomez-Ihl, C., Giai, J., Barbado, M., Paris, A., Touati, S., Alcaraz, J. P., Tanguy, S., Leroy, C., Lehmann, A., Degano, B., Gavard, M., Bedouch, P., Pavese, P., Moreau-Gaudry, A., Roustit, M., Boucher, F., Cinquin, P., & Brion, J. P. (2024). H 2 inhalation therapy in patients with moderate COVID-19 (H 2 COVID): a prospective ascending-dose phase I clinical trial. Antimicrobial Agents and Chemotherapy, 68(8). https://doi.org/10.1128/aac.00573-24

Vancouver

Salomez-Ihl C, Giai J, Barbado M, Paris A, Touati S, Alcaraz JP, et al. H 2 inhalation therapy in patients with moderate COVID-19 (H 2 COVID): a prospective ascending-dose phase I clinical trial. Antimicrobial Agents and Chemotherapy. 2024;68(8). doi:10.1128/aac.00573-24

BibTeX
@article{SalomezIhl2024,
  author = {Salomez-Ihl, C and Giai, J and Barbado, M and Paris, A and Touati, S and Alcaraz, J P and Tanguy, S and Leroy, C and Lehmann, A and Degano, B and Gavard, M and Bedouch, P and Pavese, P and Moreau-Gaudry, A and Roustit, M and Boucher, F and Cinquin, P and Brion, J P},
  title = {H 2 inhalation therapy in patients with moderate COVID-19 (H 2 COVID): a prospective ascending-dose phase I clinical trial},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  volume = {68},
  number = {8},
  doi = {10.1128/aac.00573-24}
}
Kostenlos starten →